Plasma pTau-181 predicted tau PET positivity (AUC and accuracy >90%) and amyloid-PET positivity (AUC = 0.88 and accuracy > 80%) in patients with MCI, AD, and FTD. Here, MAPT is linked to Alzheimer disease.